DOP2017000244A - Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap) - Google Patents

Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)

Info

Publication number
DOP2017000244A
DOP2017000244A DO2017000244A DO2017000244A DOP2017000244A DO P2017000244 A DOP2017000244 A DO P2017000244A DO 2017000244 A DO2017000244 A DO 2017000244A DO 2017000244 A DO2017000244 A DO 2017000244A DO P2017000244 A DOP2017000244 A DO P2017000244A
Authority
DO
Dominican Republic
Prior art keywords
flap
inhibitors
useful
activating protein
lipoxygenase activating
Prior art date
Application number
DO2017000244A
Other languages
English (en)
Inventor
Olof Broddefalk Johan
Fredrik Emtenas Hans
Lars Granberg Kenneth
Anita Lemurell Malin
Tor Pettersen Daniel
Thomas Plowright Alleyn
Johan Andreas Ulander Lars
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of DOP2017000244A publication Critical patent/DOP2017000244A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44Oxygen and nitrogen or sulfur and nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/50Acylated on said nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente solicitud se refiere a compuestos de fórmula (I) a su utilidad para tratar y/o prevenir afecciones clínicas incluyendo enfermedades cardiovasculares (ECV), a métodos para su uso terapéutico, a composiciones farmacéuticas que los contienen y a procesos para preparar dichos compuestos.
DO2017000244A 2015-05-04 2017-10-20 Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap) DOP2017000244A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562156424P 2015-05-04 2015-05-04

Publications (1)

Publication Number Publication Date
DOP2017000244A true DOP2017000244A (es) 2017-11-15

Family

ID=55910253

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000244A DOP2017000244A (es) 2015-05-04 2017-10-20 Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)

Country Status (38)

Country Link
US (5) US10183947B2 (es)
EP (2) EP3670499B1 (es)
JP (1) JP6564062B2 (es)
KR (1) KR102623474B1 (es)
CN (1) CN107646036B (es)
AR (1) AR104512A1 (es)
AU (1) AU2016258874B2 (es)
BR (1) BR112017022757B1 (es)
CA (1) CA2983668C (es)
CL (1) CL2017002660A1 (es)
CO (1) CO2017011506A2 (es)
CR (1) CR20170513A (es)
CY (2) CY1122689T1 (es)
DK (2) DK3670499T3 (es)
DO (1) DOP2017000244A (es)
EA (1) EA032221B1 (es)
ES (2) ES2760466T3 (es)
GT (1) GT201700220A (es)
HK (1) HK1245255A1 (es)
HR (2) HRP20211993T1 (es)
HU (2) HUE047445T2 (es)
IL (1) IL255069B (es)
LT (1) LT3670499T (es)
ME (1) ME03663B (es)
MX (1) MX2017013571A (es)
MY (1) MY186647A (es)
PE (1) PE20180247A1 (es)
PH (1) PH12017502112A1 (es)
PL (2) PL3292105T3 (es)
PT (2) PT3670499T (es)
RS (2) RS62729B1 (es)
SG (1) SG11201708558RA (es)
SI (2) SI3292105T1 (es)
SV (1) SV2017005549A (es)
TN (1) TN2017000458A1 (es)
TW (1) TWI718146B (es)
WO (1) WO2016177703A1 (es)
ZA (1) ZA201708189B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211993T1 (hr) * 2015-05-04 2022-04-01 Astrazeneca Ab Derivati pirazola korisni kao inhibitori proteina (flap) koji aktivira 5-lipoksigenazu
MY188809A (en) 2016-10-28 2022-01-05 Astrazeneca Ab Crystalline form of (1r,2r)-2-[4-(3-methy1-1h-pyrazol-5-yl)benzoyl]-n-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide
CN110169969B (zh) * 2019-06-28 2022-05-27 南京医科大学 Mk571在制备预防和治疗心脏病药物中应用
CN111084775A (zh) * 2020-02-17 2020-05-01 牡丹江医学院 一种用于治疗癫痫的药物组合物
CN111419800B (zh) * 2020-04-23 2021-03-19 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 用于***的药物制剂及其制备方法
CN111643498B (zh) * 2020-07-20 2021-05-07 黑龙江中医药大学 一种治疗肾结石的药物组合物及其用途
CN111714499B (zh) * 2020-07-27 2021-05-11 黑龙江中医药大学 一种用于治疗***的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP9400632A0 (en) 1993-04-29 1995-10-07 Zeneca Ltd Ether derivatives.
US5773422A (en) 1996-01-29 1998-06-30 Komer; Gene Avermectin formulation
US20070275962A1 (en) * 2003-09-10 2007-11-29 Gpc Biotech Ag Heterobicyclic Compounds as Pharmaceutically Active Agents
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
TW200815351A (en) * 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
EP2114876A4 (en) 2007-02-05 2010-12-22 Amira Pharmaceuticals Inc INVERSE INDOLES AS INHIBITORS OF THE 5-LIPOXYGENASE ACTIVATION PROTEIN (FLAP)
GB0702456D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination
US20100113330A1 (en) * 2007-04-20 2010-05-06 Schering Corporation Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof
EA017249B8 (ru) * 2007-05-10 2013-01-30 Олбани Молекьюлар Рисерч, Инк. Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
JP2010540641A (ja) 2007-10-05 2010-12-24 アミラ ファーマシューティカルス,インコーポレーテッド 5−リポキシゲナーゼ活性化タンパク質(flap)阻害剤
HRP20211993T1 (hr) * 2015-05-04 2022-04-01 Astrazeneca Ab Derivati pirazola korisni kao inhibitori proteina (flap) koji aktivira 5-lipoksigenazu

Also Published As

Publication number Publication date
ZA201708189B (en) 2018-11-28
HRP20211993T1 (hr) 2022-04-01
RS59671B1 (sr) 2020-01-31
US20200157113A1 (en) 2020-05-21
EA201792341A1 (ru) 2018-05-31
CN107646036A (zh) 2018-01-30
BR112017022757A2 (pt) 2018-07-17
PE20180247A1 (es) 2018-02-02
AU2016258874B2 (en) 2020-04-30
HK1245255A1 (zh) 2018-08-24
US10183947B2 (en) 2019-01-22
ES2902139T3 (es) 2022-03-25
HUE056875T2 (hu) 2022-03-28
EP3292105B1 (en) 2019-10-02
US20210355127A1 (en) 2021-11-18
CO2017011506A2 (es) 2018-01-31
DK3670499T3 (da) 2022-01-03
EP3292105A1 (en) 2018-03-14
GT201700220A (es) 2018-12-19
CN107646036B (zh) 2020-05-19
WO2016177703A1 (en) 2016-11-10
BR112017022757B1 (pt) 2023-02-23
SV2017005549A (es) 2018-03-12
PT3670499T (pt) 2021-12-24
SI3670499T1 (sl) 2022-02-28
US11691978B2 (en) 2023-07-04
US20190084991A1 (en) 2019-03-21
PH12017502112B1 (en) 2018-05-07
SG11201708558RA (en) 2017-11-29
EA032221B1 (ru) 2019-04-30
ES2760466T3 (es) 2020-05-14
US20180237439A1 (en) 2018-08-23
IL255069B (en) 2019-12-31
PT3292105T (pt) 2019-12-13
PL3670499T3 (pl) 2022-02-14
RS62729B1 (sr) 2022-01-31
LT3670499T (lt) 2021-12-27
EP3670499A1 (en) 2020-06-24
SI3292105T1 (sl) 2020-01-31
ME03663B (me) 2020-07-20
US11001589B2 (en) 2021-05-11
PH12017502112A1 (en) 2018-05-07
PL3292105T3 (pl) 2020-04-30
US10508119B2 (en) 2019-12-17
AU2016258874A1 (en) 2017-12-14
NZ737672A (en) 2020-11-27
MY186647A (en) 2021-08-03
TN2017000458A1 (en) 2019-04-12
KR20180002784A (ko) 2018-01-08
KR102623474B1 (ko) 2024-01-09
CY1122689T1 (el) 2021-03-12
TWI718146B (zh) 2021-02-11
JP2018514535A (ja) 2018-06-07
EP3670499B1 (en) 2021-09-29
JP6564062B2 (ja) 2019-08-21
CA2983668A1 (en) 2016-11-10
CR20170513A (es) 2018-02-13
US20230219967A1 (en) 2023-07-13
DK3292105T3 (da) 2019-12-09
CY1125179T1 (el) 2023-03-24
TW201713625A (zh) 2017-04-16
CA2983668C (en) 2023-06-27
IL255069A0 (en) 2017-12-31
HRP20192172T1 (hr) 2020-02-21
CL2017002660A1 (es) 2018-04-13
HUE047445T2 (hu) 2020-04-28
MX2017013571A (es) 2018-02-26
AR104512A1 (es) 2017-07-26

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
DOP2017000244A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
CO2017011851A2 (es) Compuestos novedosos
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
BR112016023558A2 (pt) compostos úteis como imunomoduladores
UY36285A (es) Compuestos que inhiben la proteína mcl-1
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112014009006B8 (pt) Compostos heterocíclicos e métodos de uso dos mesmos
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
BR112016001645A8 (pt) derivados de oxoquinazolinil-butanamida, seu uso, medicamentos e kit
CR20150432A (es) Estra-1,3,5 (10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
BR112017006264A2 (pt) derivados de nucleosídeo substituído com 4?-vinila como inibidores de replicação de rna do vírus sincitial respiratório
ECSP18056196A (es) Derivados de indano
BR112017021114A8 (pt) Compostos heterocíclicos como inibidores de lsd1